Saghmos Therapeutics, Inc. has announced that the US Patent and Trademark Office (USPTO) has granted US Patent No. 11,986,473 titled, 'Prevention and/or Treatment of Contrast-Induced Acute Kidney Injury' for its Phase 3-ready product, ST-62516 (trimetazidine), a cardiorenal metabolic modulator.

The patent provides exclusivity through 2037, with broad claims for the reduction of Acute Kidney Injury (AKI) and Major Adverse Cardiac and Kidney Events (MACKE) in patients undergoing procedures with contrast dyes.

Saghmos is developing ST-62516 to reduce the risk of AKI and MACKE after contrast procedures such as percutaneous coronary intervention (PCI). The interrelationship between cardiovascular disease, kidney disease, and metabolic disease has recently been termed CKM Syndrome. Patients with this syndrome are at increased risk of adverse cardiovascular and kidney outcomes after contrast procedures such as PCI. ST-62516 is uniquely positioned to address this unmet need.

"We are excited about the continued growth of Saghmos’ intellectual property estate, which now has two issued US patents as well as an issued patent in Japan,” commented Anna Kazanchyan, MD, Founder and CEO of Saghmos Therapeutics.

According to the American Heart Association, one in three US adults have three or more risk factors for CKM. Over one million PCI procedures are performed annually in the US and about half of these individuals have CKM Syndrome, or are aged 75 and older.

CKM Syndrome in combination with certain procedure-related factors, adversely affects the safety of PCI and increases the risk of AKI and MACKE. This is a major unmet medical need with no FDA-approved drugs available. ST-62516 could benefit all people undergoing a PCI, not just those with CKM Syndrome, by reducing the threat of AKI and MACKE after PCI.